On January 13, 2026 Applied Cells Inc. reported a strategic collaboration framework with Immuneel Therapeutics Private Limited to jointly evaluate the application of Applied Cells’ MARS Atlas platform and GoFast CAR-T workflow for future CAR-T therapy development and manufacturing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under this collaboration, the two companies will work together to integrate the MARS Atlas platform and GoFast workflow into selected Immuneel CAR-T programs. The shared objective is to significantly improve the affordability and accessibility of CAR-T therapies, beginning in India, with the potential for broader global adoption.
A key focus of the collaboration is achieving manufacturing costs that enable truly affordable CAR-T therapy for the majority of eligible patients in India, while maintaining therapeutic efficacy comparable to currently approved CAR-T treatments. ‘We are thrilled to partner with Immuneel, a pioneer in bringing cutting‑edge cell therapies to India,’ said Yuchen Zhou, CEO of Applied Cells. ‘The combination of MARS Atlas and the GoFast workflow with Immuneel’s clinical and regulatory capabilities has the potential to transform the CAR‑T landscape by making these life‑saving treatments accessible to millions who currently cannot afford them.’
‘At Immuneel, our mission is to make advanced cell therapies accessible and affordable for patients who need them the most,’ said Amit Mookim, CEO of Immuneel Therapeutics. ‘This collaboration represents an important step in evaluating innovative technologies that could strengthen our manufacturing capabilities and support development of scalable, cost‑effective CAR‑T solutions. We look forward to jointly exploring how platforms like MARS Atlas and the GoFast workflow could contribute to expanding access to high‑quality cell therapies in India and beyond.’
Both companies have commenced collaborative activities and will share updates as the programs progress.
(Press release, Applied Cells, JAN 13, 2026, https://appliedcells.com/immuneel-cart-collaboration/ [SID1234662008])